Skip to main content

Fortress Biotech, Inc.

FBIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001429260

In the last 90 days, Fortress Biotech, Inc. insiders filed 2 open-market purchases and 0 sales; 59 institutions reported holding it in 13F filings for Q3 2026, worth $17.7M in total; no superinvestor holds it.

Other share classesFBIOP

Key figures

Market capNo recent share count in SEC filings
–
Insider buysLast 90 days, $340.4K in total
2
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +4 vs. previous quarter
59
13F valueReported value at the end of Q3 2026
$17.7M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$63.3M
+9.7% year over year
Net income, FY2025
$6.82M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
$19.2M
+8.7% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net income for FY2025: $6.82M (10.8% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
4.61M
Shares sold short
Change
+88.3K
+2.0% vs. previous
Days to cover
23.59
At average daily volume

Superinvestors holding FBIO, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding FBIO at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Fortress Biotech, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 19, 2026 (view filing)5:59 PM ETNov 17-192 daysRosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMANPPurchaseCommon Stock, par value $0.001+136.7K$1.85+$252.6K+3.0%4.72M after3 lots
Nov 19, 2026 (view filing)5:54 PM ETNov 17-192 daysJin DavidChief Financial OfficerPPurchaseCommon Stock, par value $0.001+47.6K$1.84+$87.8K+2.9%1.70M after3 lots
Sep 25, 2024 (view filing)4:45 PM ETSep 232 daysRosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMANPPurchaseCommon stock, par value $0.001+763.4K$1.84+$1.40M+26.4%3.66M after
Sep 25, 2024 (view filing)4:45 PM ETSep 232 daysRosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMANPPurchase+763.4K$0.125+$95.4K–763.4K afterDerivative
Jul 15, 2024 (view filing)Jul 114 daysRosenwald Lindsay A MDPresident, CEO & ChairmanPPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK+5.00K$7.48+$37.4K+4.1%127.5K after
Jul 12, 2024 (view filing)Jul 102 daysJin DavidChief Financial OfficerPPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK+500$7.50+$3.75KNew position500 after
Jul 11, 2024 (view filing)Jul 92 daysRosenwald Lindsay A MDPresident, CEO & ChairmanPPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK+5.00K$7.39+$37.0K+4.3%122.5K after
Jul 10, 2024 (view filing)Jul 82 daysRosenwald Lindsay A MDPresident, CEO & ChairmanPPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK+5.00K$7.35+$36.8K+4.4%117.5K after
Jul 1, 2024 (view filing)Jun 283 daysRosenwald Lindsay A MDPresident, CEO & ChairmanPPurchaseCOMMON STOCK, PAR VALUE $0.001+20.0K$1.64+$32.8K+0.7%2.89M after
May 20, 2024 (view filing)May 164 daysRosenwald Lindsay A MDPresident, CEO & ChairmanPPurchaseCOMMON STOCK, PAR VALUE $0.001+10.0K$1.76+$17.6K+0.3%2.87M after

Top 10 13F holders, Q3 2026

See all 59 holders

The largest institutional positions in Fortress Biotech, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding FBIO in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Millennium Management LLC2,165,401$4.63M0.00%+2,165,401New
Vanguard Capital Management LLC1,037,203$2.22M0.00%00.0%Unchanged
Opaleye Management Inc.720,000$1.54M0.17%−170,000−19.1%Reduced
Mackenzie Financial Corp528,913$1.13M0.00%−26,763−4.8%Reduced
Acadian Asset Management LLC459,016$981.0K0.00%+351,713+327.8%Added
Shikiar Asset Management Inc305,469$654.0K0.16%00.0%Unchanged
Geode Capital Management, LLC285,178$610.5K0.00%−15,343−5.1%Reduced
Bridgeway Capital Management, LLC227,368$486.6K0.01%+50,000+28.2%Added
Panagora Asset Management Inc226,593$484.9K0.00%+160,568+243.2%Added
BlackRock, Inc.220,714$472.3K0.00%−4,068−1.8%Reduced

Holders of 5% or more of FBIO

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Fortress Biotech, Inc..

Largest holders of FBIO from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Rosenwald Lindsay A MD13D/A20.70%6.92M shares–Nov 21, 20234 filingsMar 20, 2026SEC
Highbridge Capital Management LLC13G/A7.80%2.73M shares–Oct 25, 20242 filingsMay 15, 2026SEC
Integrated Core Strategies (US) LLC13G/A6.50%2.17M shares+1.20 ppfrom 5.30%Sep 1, 20262 filingsOct 29, 2026SEC